普洛藥業(000739.SZ):鹽酸帕洛諾司瓊注射液獲批
格隆匯7月7日丨普洛藥業(000739.SZ)公佈,近日,公司之全資子公司浙江優勝美特中藥有限公司收到國家藥品監督管理局核准簽發的關於鹽酸帕洛諾司瓊注射液的《藥品註冊證書》。
鹽酸帕洛諾司瓊注射液適用於:(1)預防重度致吐化療引起的急性惡心、嘔吐;(2)預防中度致吐化療引起的噁心、嘔吐。
據米內網數據顯示,帕洛諾司瓊製劑2020年和2021年在國內城市公立醫院、縣級公立醫院及鄉鎮衞生院終端銷售總額分別為16.36億元、16.23億元。其中,該注射劑2020年和2021年銷售金額分別為15.37億元、14.36億元。
該藥品視同通過仿製藥質量和療效一致性評價。該證書的獲得是公司原料藥製劑一體化戰略的重要體現,有利於進一步提升該產品的市場競爭力,對公司經營發展具有一定的積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.